New England Research & Management Inc. Cuts Stock Holdings in United Therapeutics Corporation $UTHR

New England Research & Management Inc. cut its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 19.6% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 4,440 shares of the biotechnology company’s stock after selling 1,085 shares during the quarter. New England Research & Management Inc.’s holdings in United Therapeutics were worth $1,861,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. CWM LLC increased its position in United Therapeutics by 204.3% during the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after purchasing an additional 3,487 shares in the last quarter. AXQ Capital LP lifted its position in United Therapeutics by 495.4% during the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after buying an additional 3,235 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in United Therapeutics by 77.4% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after buying an additional 2,655 shares during the period. State of Alaska Department of Revenue increased its position in shares of United Therapeutics by 17.0% in the second quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company’s stock worth $5,612,000 after acquiring an additional 2,840 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in shares of United Therapeutics by 60.0% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,067 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 400 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of recent research reports. HC Wainwright increased their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. UBS Group upped their target price on shares of United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Finally, Royal Bank Of Canada raised their price target on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $505.00.

United Therapeutics Trading Up 1.3%

United Therapeutics stock opened at $500.30 on Tuesday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $501.05. The stock has a market cap of $21.54 billion, a P/E ratio of 18.96, a price-to-earnings-growth ratio of 4.90 and a beta of 0.86. The stock has a 50 day moving average of $458.75 and a 200-day moving average of $376.11.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm’s quarterly revenue was up 6.8% on a year-over-year basis. During the same period in the prior year, the company posted $6.39 earnings per share. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Martine A. Rothblatt sold 4,000 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $490.70, for a total transaction of $1,962,800.00. Following the sale, the chief executive officer directly owned 130 shares of the company’s stock, valued at approximately $63,791. This represents a 96.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Nilda Mesa sold 187 shares of United Therapeutics stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $481.63, for a total transaction of $90,064.81. Following the completion of the transaction, the director directly owned 5,286 shares of the company’s stock, valued at approximately $2,545,896.18. This represents a 3.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 608,037 shares of company stock valued at $274,519,153 over the last three months. Company insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.